[CLSN] Celsion Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.36 Change: 0.01 (2.77%)
Ext. hours: Change: 0 (0%)

chart CLSN

Refresh chart

Strongest Trends Summary For CLSN

CLSN is in the long-term down -99% below S&P in 9 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company?s lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; under Phase II clinical trials for recurrent chest wall breast cancer; and in phase II clinical trials for colorectal liver metastasis. It has a development, product supply, and commercialization agreement with Yakult Honsha Co. Ltd. for ThermoDox; and a commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. for the production of ThermoDox in mainland China, Hong Kong, and Macau. The company was founded in 1982 and is based in Lawrenceville, New Jersey.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 0% Sales Growth - Q/Q0% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-45.29% ROE-101.39% ROI-58.71%
Current Ratio2.98 Quick Ratio Long Term Debt/Equity0.25 Debt Ratio0.39
Gross Margin Operating Margin-5185.2% Net Profit Margin-5415.2% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-880 K Cash From Investing Activities1.74 M Cash From Operating Activities-5.94 M Gross Profit
Net Profit-7.01 M Operating Profit-6.59 M Total Assets59.78 M Total Current Assets30.67 M
Total Current Liabilities10.29 M Total Debt8.94 M Total Liabilities33.08 M Total Revenue120 K
Technical Data
High 52 week3.32 Low 52 week1.36 Last close2.17 Last change-1.36%
RSI51.25 Average true range0.1 Beta0.49 Volume760.88 K
Simple moving average 20 days0.5% Simple moving average 50 days10.75% Simple moving average 200 days-11.23%
Performance Data
Performance Week-1.81% Performance Month0.46% Performance Quart17.93% Performance Half-14.23%
Performance Year-3.56% Performance Year-to-date53.9% Volatility daily1.6% Volatility weekly3.59%
Volatility monthly7.35% Volatility yearly25.47% Relative Volume626.49% Average Volume109.38 K
New High New Low

News

2019-04-17 08:14:12 | Ultragenyx's RARE UX007 Gets Fast Track Status by FDA

2019-04-17 08:00:00 | Celsion Corporation Announces Issuance of New Patent for ThermoDox®

2019-04-16 19:26:11 | ProQR Initiates Dosing in Phase II/III Eye Disorder Study

2019-04-12 08:30:00 | Celsion Corporation to Participate in Two Investor Conferences in May 2019

2019-04-12 08:00:00 | Celsion Corporation to Hold First Quarter 2019 Financial Results Conference Call on Wednesday, May 15, 2019

2019-04-11 12:34:00 | SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Celsion Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors

2019-04-03 09:00:01 | Celsion CLSN Moves to Strong Buy: Rationale Behind the Upgrade

2019-03-29 18:23:08 | Edited Transcript of CLSN earnings conference call or presentation 29-Mar-19 3:00pm GMT

2019-03-29 08:00:00 | Celsion Corporation Reports 2018 Financial Results

2019-03-22 08:30:00 | Celsion Corporation to Hold Year-End 2018 Financial Results Conference Call on Friday, March 29, 2019

2019-03-04 08:30:00 | Celsion Announces GEN-1 Data Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium

2019-02-21 16:30:00 | Celsion Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2019-02-01 07:30:00 | Consolidated Research: 2019 Summary Expectations for Southwest Airlines, Southern Copper, SEI Investments, Forward Air, Cincinnati Financial, and Celsion — Fundamental Analysis, Key Performance Indications

2019-01-24 11:30:00 | Celsion Corporation to Present at NobleConXV – Noble Capital Markets’ 15th Annual Investor Conference

2019-01-17 08:30:00 | Celsion Announces Publication of ThermoDox® Study Results in Radiology

2019-01-15 08:30:00 | Celsion Announces Presentation of GEN-1 Data at Upcoming ASCO-SITC Clinical Immuno-Oncology Symposium

2018-12-18 08:00:00 | Data Monitoring Committee DMC Completes Planned Safety and Data Review of Celsion’s Phase III OPTIMA Study of ThermoDox® for Treatment of Primary Liver Cancer

2018-12-03 09:15:00 | Celsion Receives $11.1 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer NOL Program

2018-11-21 14:53:36 | Analysts Take Action on Health Care Stocks

2018-11-15 13:27:12 | Edited Transcript of CLSN earnings conference call or presentation 15-Nov-18 4:00pm GMT

2018-11-14 16:30:00 | Celsion Corporation Reports Third Quarter 2018 Financial Results and Provides Business Update

2018-11-08 09:15:00 | Celsion Corporation to Hold Third Quarter 2018 Financial Results Conference Call on Thursday, November 15, 2018

2018-10-25 08:40:00 | Report: Exploring Fundamental Drivers Behind The ExOne, Switch, Monotype Imaging, Celsion, TrueCar, and Sandstorm Gold — New Horizons, Emerging Trends, and Upcoming Developments

2018-10-24 09:25:00 | Celsion Announces Progression-Free Survival Data From GEN-1 Phase I Immuno-Oncology Study of Patients with Stage III/IV Ovarian Cancer

2018-10-22 09:20:00 | Celsion Announces Publication Highlighting the Potential of Celsion's Gene-Mediated Immunotherapy to Improve Administration of IL-12 and Progression-Free Survival in Ovarian Cancer Patients

2018-10-03 17:15:00 | Celsion Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2018-09-17 08:30:00 | Celsion Appoints Marianne Lambertson as Vice President of Communications and Investor Relations

2018-09-16 14:22:16 | The Week Ahead In Biotech Sept. 16-22: Conferences, PDUFA Dates, Clinical Trial Results And IPOs

2018-09-06 08:00:00 | Celsion Announces First Patient Randomized in the Gene-Mediated Immunotherapy GEN-1 Study of Newly Diagnosed Stage III/IV Ovarian Cancer Patients

2018-09-05 08:00:00 | Celsion Announces Enrollment Completion for Pivotal Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer

2018-09-05 07:30:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Aerie Pharmaceuticals, BioScrip, Celsion, Primoris Services, Cyclacel Pharmaceuticals, and Barnes Group — New Research Emphasizes Economic Growth

2018-09-04 08:30:00 | Celsion Strengthens Its Balance Sheet with the Approval of Its Application to Sell Net Operating Losses for up to $10 Million in Non-Dilutive Funding

2018-08-16 08:00:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Celsion, Alpha and Omega Semiconductor, SP Plus, Merrimack Pharmaceuticals, La Jolla Pharmaceutical, and SPX — New Research Emphasizes Economic Growth

2018-08-14 15:40:51 | Edited Transcript of CLSN earnings conference call or presentation 14-Aug-18 3:00pm GMT

2018-08-14 09:00:00 | Celsion Corporation to Host Earnings Call

2018-08-14 08:30:00 | Celsion Corporation Reports Second Quarter 2018 Financial Results and Provides Business Update

2018-08-07 09:00:00 | Celsion Corporation to Hold Second Quarter 2018 Financial Results Conference Call on Tuesday, August 14, 2018

2018-07-13 07:43:11 | Zacks.com highlights: Rosehill Resources, Navios Maritime Partners, AMC Entertainment Holdings, Entercom Communications and Celsion

2018-07-12 09:12:01 | 5 Cheap Breakout Stocks for Formidable Returns

2018-07-10 08:00:00 | CELSION ANNOUNCES PUBLICATION OF THERMODOX® PHASE I CLINICAL STUDY RESULTS IN THE LANCET ONCOLOGY

2018-06-30 17:32:56 | The Week Ahead In Biotech: Delayed Clinical Trial Releases In Focus

2018-06-29 09:33:01 | Celsion CLSN Shares March Higher, Can It Continue?

2018-06-29 09:11:01 | 4 Biotech Stocks to Bet on in the Second Half of 2018

2018-06-28 08:30:00 | Celsion Corporation Announces Strategic Loan Facility

2018-06-25 08:00:00 | Celsion Corporation to Join Russell Microcap® Index

2018-06-20 08:00:00 | Today's Research Reports on Trending Tickers: Celsion and Spark Therapeutics

2018-06-06 14:10:20 | Celsion Corporation NASDAQ:CLSN: Has Recent Earnings Growth Beaten Long-Term Trend?

2018-05-28 12:02:14 | Best NasdaqGS Growth Companies

2018-05-15 07:30:00 | Analysis: Positioning to Benefit within United Natural Foods, Capitol Federal Financial, Royal Gold, Celsion, National CineMedia, and Nu Skin Enterprises — Research Highlights Growth, Revenue, and Consolidated Results

2018-05-11 17:56:40 | Edited Transcript of CLSN earnings conference call or presentation 11-May-18 3:00pm GMT